Skip to content
sellWeak cluster of 5

INGENITO GARY sold $273k of CPRX

Chief Med. & Reg. Officer at CATALYST PHARMACEUTICALS, INC.. 12,000 shares at an average of $22.72, traded Nov 27, 2024, filed Nov 29, 2024.

Warning score
33
Value
$273k
12,000 shares
Holdings after
51,391
-19% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet

What happened after comparable sells

Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.

Rows in this filing

Every transaction in Form 4 0001161697-24-000492, as filed. Open on EDGAR

DateTransactionSharesPriceValueHoldings afterFiled
Nov 27, 2024MOption exercise
Common stock, par value $0.001 per share
+12,000$4.01$48k63,391Nov 29, 2024
Nov 27, 2024SOpen-market sale
Common stock, par value $0.001 per share
-8,631$22.74$196k54,760Nov 29, 2024
Nov 27, 2024SOpen-market sale
Common stock, par value $0.001 per share
-3,369$22.67$76k51,391Nov 29, 2024
Nov 27, 2024MOption exercise
Options to purchase common stockderivative
-12,000$0.00$01,041,631Nov 29, 2024

Related signals

Other insiders at CATALYST PHARMACEUTICALS, INC. and this insider’s other filings.

ScoreSideCompanyInsiderValueSharesFiled
40Moderatesell 4CPRX
CATALYST PHARMACEUTICALS, INC.
Miller Steve
Chief Op. & Scientific Officer
$1.1M50,000
29Weaksell 5CPRX
CATALYST PHARMACEUTICALS, INC.
Elsbernd Brian
Chief Compliance/Legal Officer
$287k13,256
51Moderatesell 5CPRX
CATALYST PHARMACEUTICALS, INC.
Harper Molly
director
$385k17,500
47Moderatesell 4CPRX
CATALYST PHARMACEUTICALS, INC.
INGENITO GARY
Chief Med. & Reg. Officer
$806k38,000
40Moderatesell 4CPRX
CATALYST PHARMACEUTICALS, INC.
MCENANY PATRICK J
director, other
$3.6M170,845
40Moderatesell 4CPRX
CATALYST PHARMACEUTICALS, INC.
MCENANY PATRICK J
director, other
$3.1M137,155
38Weaksell 2CPRX
CATALYST PHARMACEUTICALS, INC.
MCENANY PATRICK J
director, other
$12M492,000

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.